Services

Out-Licensing

We often meet biotechs with promising assets that experience difficulties - whether this is due to lack of time, connections, or strategy - in finding the right partner to develop the asset further and eventually bring them to market. Liberi Group has been assisting Biotechs for over 10 years in maximising the value of their assets and successfully licensing them out to pharmaceutical companies. Our team of experienced consultants has a proven track record of success in the biotech industry. We specialize in providing comprehensive support throughout the licensing process, from identifying potential partners to negotiating and structuring the agreement. We work closely with your team to understand your unique needs and goals, and develop a customized strategy to license out your assets and facilitate further development.

Learn more about our approach

Let's Connect!

Want to learn more about how Liberi can help you?

Get in touch

Co-Development

Co-development is a crucial aspect of the biotech industry, where companies collaborate with pharmaceutical partners to bring innovative treatments to market. As a Business Development & Strategy consultant, the team at Liberi Group provides support to biotech in their search for a co-development deal with pharmaceutical companies. This deal may provide your company with required lab space, resource sharing and knowledge exchange. Such a deal can accelerate the development of the drug without affecting your company's equity.

Our team has extensive experience and expertise in the biotech industry and a deep understanding of the complexities involved in co-development partnerships. We work closely with our clients to understand their goals and objectives and help them identify potential partners who align with their vision as well as support in the deal-making process.

Let's Connect!

Want to learn more about how Liberi can help you?

Get in touch

In-Licensing

Are you a large Biotech or Pharma trying to broaden your pipeline with assets that suit your company, but do not have the resources internally? With In-licensing projects, Liberi Group focusses on introducing assets that suit your criteria. Not only do we wish to understand what kind of assets would be complementing your pipeline, but we also keep your strategic focus in mind. Liberi Group’s in-licensing team makes use of various databases, including our global personal network, to target the right assets. We introduce assets regularly based on your criteria, facilitate introduction calls, and stay involved during the evaluation process and term negotiations. It is important to emphasize that with Liberi Group, your company remains anonymous until the moment that you wish to meet the licensor.

Let's Connect!

Want to learn more about how Liberi can help you?

Get in touch

Investment Search

Liberi Group has extensive experience in seeking funding for our clients. Due to the extensive portfolio in pre-clinical, early and late-stage clients, Liberi has built up an extensive investor network allowing us to search in all directions. The investment rounds range from angel, seed investments, series A, B, C, and Pre-IPO to Post-IPO investments. We have also gained extensive knowledge in strategizing and assisting in IPOs. Initial public offerings are a tool to attract capital and improve our clients' reputation in the global market. Over the years, we assisted in IPO’s, direct offerings, convertible notes, special purpose acquisition companies (SPAC), PIPE investments, and (reverse) mergers and acquisitions.

Learn more about our approach

Let's Connect!

Want to learn more about how Liberi can help you?

Get in touch

Divesting Assets

Within Liberi Group we work with clients in the life science industry to identify assets that are no longer aligned with their business goals and assist them in finding buyers or partners for these assets. We support these companies in finding the right partner based on the criteria and scope of the project. Divesting assets can result in an increased market valuation, support in managing risk, improved financial performance, and can bring the focus back to your core business and development of the assets that suit your business goals. In short, our service supports large biotech and pharma to make informed decisions about their assets, optimize the value of these assets, and find the appropriate partner.

Let's Connect!

Want to learn more about how Liberi can help you?

Get in touch

M&A

Within our team of 20 consultants there are multiple M&A experts. Our M&A support service is designed to assist firms in identifying and pursuing opportunities for mergers, acquisitions, and strategic partnerships. We can help you from evaluating potential buyers or partners, or identify and target interesting companies to acquire, till negotiations of the terms of the agreement. Our expert team has extensive experience in the life science industry and can provide guidance and support at every stage of the M&A process. Whether you are looking to expand your operations, access new technologies or markets, or diversify your product portfolio, we can help you achieve your business goals through M&A.

Let's Connect!

Want to learn more about how Liberi can help you?

Get in touch

Valuation Assessment

In recent years, we noticed the need for independent value services for pharmaceutical companies that are looking for in-licensing and acquisition opportunities. Therefore, we initiated our own value assessment team within Liberi Group, consisting of both financial and industry professionals.

The value of a company is a key component of any investment, M&A or licensing deal. Insights into the value of a company can be an effective tool to guide a value-based management approach and to help with strategic decisions ahead. Liberi Group Value Services offers a comprehensive set of value services, both company- and asset value assessments to biotech and pharmaceutical companies.

We make use of the risk-adjusted net present Value (rNPV) method, which is the most appropriate method to value life science products in development. This method factors in the success rates of therapeutic products in pharmaceutical development and the probability of failure. The outcome of these calculations can be utilized to evaluate the investment opportunity.

Let's Connect!

Want to learn more about how Liberi can help you?

Get in touch

Rare Disease

Liberi Group works therapeutics area agnostic; however, we do have specialists within our team that focus on the rare disease space. Our specialized database and network of contacts within the rare disease sector make us uniquely qualified to support rare disease biotech's in their search for potential partners. With a growing demand for treatments for rare diseases, we have seen an increased interest in this niche market. We acknowledge the importance of rare disease treatment developments and recognize the challenges that come with developing these assets. We are used to working with rare disease clients and understand the challenges like low prevalence, lack of disease awareness, and high development costs. The Liberi Group team will support you throughout the entire process and will focus on the challenges and opportunities that this industry faces. Whether you are looking to collaborate on research and development, license your products, or explore other strategic opportunities, we can help you succeed in this dynamic and rapidly evolving market.

Let's Connect!

Want to learn more about how Liberi can help you?

Get in touch

01

Kick-Off

Whether you are a Biotech looking for investors/strategic partners, or a Pharma looking for assets that compliment your pipeline; the first step in our collaboration is always a kick-off call. The kick-off call is the time and place to meet the team that will support you in your BD and strategy challenges.
Discussing the plan of action and addressing the science will be the two main subjects of the kick-off call. The project has been reviewed and evaluated by the team prior to signing the contract, however at Liberi Group we value a tailored approach for our clients and hence we believe it is essential for the project team to receive the information first hand. This also facilitates the necessary information needed for an extensive brainstorm on strategic positioning. After addressing the science and company background we walk through the short- and long-term plan of action and the scope of the project.

Next: Strategic positioning

02

Strategic positioning

As a Business Development and Strategy consultant we focus on translating your science to business. The first step after the kick-off call is therefore to internally discuss your materials and the information gathered during the kick-off call. We review the marketing materials (slide decks, one-pagers, etc.) and focus on two aspects: Business and Science. For the business part, we provide suggestions, based on years of experience, which facilitate the evaluation of potential partners and address potential ambiguities. Regarding the science, our scientific team will provide feedback with a business strategy in mind. Internally the feedback of the scientific team and the business experts are compiled and shared with our client.

Previous: Kick-off

Next: Outreach proposal

03

Outreach proposal

Based on the information from the kick-off call, internal discussions, the non-confidential slide deck and the scope that was decided upon, our team will draft a list of potential partners, both Pharma and Investors. This proposed outreach list is based on multiple sources, among which insight information of our personal network. We value our personal network and understand their needs and wants. This does not only benefit us and our clients, but also our network since we carefully select which clients we introduce, based on the criteria and interest of the potential partner/investor.

After compiling the outreach list, we send it over to our client for feedback. This is the right time to discuss potential past communications and experiences. It is of importance that we have a final list of companies that both parties feel comfortable with, before we pursue next steps. An important side note is that our networking activities often leads to mutations in our internal database. As a result, we periodically update the potential partner list by adding companies or informing our clients that their assets no longer fit the search scope of a company. Naturally, this means our outreach process is iterative and that “Step 4” is a reoccurring step.

Previous: Strategic positioning

Next: Outreach phase

04

Initiating contact

After your approval of the outreach list and the slide deck optimization, our team will initiate the outreach. This is a personal outreach and can be focussed on our global network, on specific regions, or both. The outreach often starts by emailing our contacts within the pharma/investors which allows us to attach all non-confidential information that we wish to provide for an initial review. After sending over the initial email, we follow up via meetings, phone calls, and various other methods.

As mentioned before, we will regularly compare and analyse the agreed list with our database to see whether some potential partners have changed their search scope away from our client’s projects and whether new potential partners have derived from our networking activities. Normally we work in cycles of 2 months in updating the outreach lists, however we will inform clients on new potential partners resulting from events (e.g., conferences or business trips) on a timely manner to not miss the window of opportunity.

Previous: Outreach proposal

Next: Monthly updates

05

Monthly updates

Throughout our collaboration we will keep you up to date on the feedback and responses we receive from our network. We schedule monthly update calls to discuss and reflect on the ongoing process and on next steps forward. In preparation of these update calls, the team will share a detailed written update sheet consisting of all the responses, temporal conclusions, and action plans for the upcoming period. Not all potential partners will provide feedback at the same pace, therefore we regularly follow up on the companies that are in review or have yet to respond.

Previous: Inititating contact

Next: Continuous engagement

06

Continuous engagement

After introducing your science to our network, we engage in next steps with the interested parties. We will support you in all steps of the partnering/investment process as your virtual Business Development team. We will set-up calls with the interested party and will join those calls as well to guide discussions where necessary. We help with drawing up Confidential Disclosure Agreements (CDA’s) and with finalising and structuring the Virtual Data Room (VDR). Throughout the confidential evaluation, we stay in touch with the pharma or investor to support them in their evaluation where necessary. While aligning interested companies, we will also continuously reach out to newly added companies to our database and stay connected to companies who wish to await further data.

Previous: Monthly updates

Next: Partner discussions

07

Partner discussions

As soon as interested parties move to term sheets, we support you in negotiating, evaluating, and setting terms. This step can be seen as one of the most important steps of the process. During these discussions, we work on setting the right terms, together with you, which will benefit the development of your portfolio. Based on our extensive dealmaking experience, we can guide you during this process as an extension of your management team to maximize value for both parties.

Previous: Continuous engagement

Next: Next steps?

08

Next steps?

A collaboration with Liberi Group is a collaboration between your and our company. We do not work project wise but wish to support you on all aspects of your Business Development and Strategy. This means that after closing a successful deal and some celebrations we discuss the next steps of our collaboration. Is there a preference to transition the new partnership towards a merger or acquisition? Or are there other assets you want us to continue working on? A successful collaboration ends with flowers on your desk and is only completed when both parties are enthusiastic and eager for future developments. Are you eager to explore a potential collaboration with Liberi Group? Let’s connect!

Previous: Partner discussions

Get in touch